Your browser doesn't support javascript.
loading
Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.
Mohebi, Reza; Karimi Galougahi, Keyvan; Garcia, Javier Jas; Horst, Jennifer; Ben-Yehuda, Ori; Radhakrishnan, Jai; Chertow, Glenn M; Jeremias, Allen; Cohen, David J; Cohen, David J; Maehara, Akiko; Mintz, Gary S; Chen, Shmuel; Redfors, Björn; Leon, Martin B; Stuckey, Thomas D; Rinaldi, Michael J; Weisz, Giora; Witzenbichler, Bernhard; Kirtane, Ajay J; Mehran, Roxana; Dangas, George D; Stone, Gregg W; Ali, Ziad A.
Afiliación
  • Mohebi R; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Karimi Galougahi K; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Garcia JJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Horst J; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Ben-Yehuda O; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Radhakrishnan J; Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
  • Chertow GM; Division of Nephrology, Departments of Medicine and Epidemiology and Population Health, Stanford University, Stanford, California, USA.
  • Jeremias A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; DeMatteis Cardiovascular Institute, St. Francis Hospital, Roslyn, New York, USA.
  • Cohen DJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; DeMatteis Cardiovascular Institute, St. Francis Hospital, Roslyn, New York, USA.
  • Cohen DJ; Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
  • Maehara A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Mintz GS; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Chen S; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Redfors B; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA; Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.
  • Leon MB; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Stuckey TD; LeBauer-Brodie Center for Cardiovascular Research and Education, Cone Health, Greensboro, North Carolina, USA.
  • Rinaldi MJ; Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.
  • Weisz G; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Witzenbichler B; Department of Cardiology and Pneumology, Helios Amper-Klinikum, Dachau, Germany.
  • Kirtane AJ; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.
  • Mehran R; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Dangas GD; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Stone GW; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Ali ZA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; DeMatteis Cardiovascular Institute, St. Francis Hospital, Roslyn, New York, USA. Electronic address: zali@crf.org.
JACC Cardiovasc Interv ; 15(7): 753-766, 2022 04 11.
Article en En | MEDLINE | ID: mdl-35305904
ABSTRACT

OBJECTIVES:

This study sought to determine correlates and consequences of contrast-associated acute kidney injury (CA-AKI) on clinical outcomes in patients with or without pre-existing chronic kidney disease (CKD).

BACKGROUND:

The incidence and impact of CA-AKI on clinical outcomes during contemporary percutaneous coronary intervention (PCI) are not fully defined.

METHODS:

The ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents) study was a prospective, multicenter registry of 8,582 patients treated with ≥1 drug-eluting stent(s). CA-AKI was defined as a post-PCI increase in serum creatinine of >0.5 mg/dL or a relative increase of ≥25% compared with pre-PCI. CKD was defined as estimated glomerular filtration rate <60 mL/min/1.73 m2. The primary endpoint was the 2-year rate of net adverse clinical events (NACE) All-cause mortality, myocardial infarction (MI), definite or probable stent thrombosis, or major bleeding.

RESULTS:

Of 7287 (85%) patients with evaluable data, 476 (6.5%) developed CA-AKI. In a multivariable model, older age, female sex, Caucasian race, congestive heart failure, diabetes, hypertension, CKD, presentation with ST-segment elevation MI, Killip class II to IV, radial access, intra-aortic balloon pump use, hypotension, and number of stents were independent predictors of CA-AKI. The 2-year NACE rate was higher in patients with CA-AKI (adjusted HR 1.88; 95% CI 1.42-2.49), as was each component of NACE (all-cause mortality, HR 1.77; 95% CI 1.22-2.55; MI, HR 1.67; 95% CI 1.18-2.36; definite/probable stent thrombosis, HR 1.71; 95% CI 1.10-2.65; and major bleeding, HR 1.38; 95% CI 1.06-1.80). Compared with the CA-AKI-/CKD- group, the CA-AKI+/CKD- (HR 1.83; 95% CI 1.33-2.52), CA-AKI-/CKD+ (HR 1.56; 95% CI 1.15-2.13), CA-AKI+/CKD+ (HR 3.29; 95% CI 1.92-5.67), and maintenance dialysis (HR 2.67; 95% CI 1.65-4.31) groups were at higher risk of NACE.

CONCLUSIONS:

CA-AKI was relatively common after contemporary PCI and was associated with increased 2-year rates of NACE. Patients with pre-existing CKD were at particularly high risk for NACE after CA-AKI.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Insuficiencia Renal Crónica / Stents Liberadores de Fármacos / Lesión Renal Aguda / Intervención Coronaria Percutánea / Infarto del Miocardio Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: JACC Cardiovasc Interv Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Insuficiencia Renal Crónica / Stents Liberadores de Fármacos / Lesión Renal Aguda / Intervención Coronaria Percutánea / Infarto del Miocardio Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: JACC Cardiovasc Interv Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos